within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC01_Omeprazole;

model Omeprazole_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.333333333333334e-06,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.00035,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00023999999999999998,
    k12 = 4.444444444444444e-06,
    k21 = 4.444444444444444e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Omeprazole_1</td></tr><tr><td>ATC code:</td><td>A02BC01_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.35</td><td>L</td></tr>
    <tr><td>clearance:</td><td>500</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Omeprazole is a proton pump inhibitor that blocks gastric acid secretion and is used for acid-related gastrointestinal disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy subjects after single 40 mg intravenous bolus administration.</p><h4>References</h4><ol><li><p>Solana, MJ, et al., &amp; Carrillo, A (2014). Population pharmacokinetics of omeprazole in critically ill pediatric patients. <i>Therapeutic drug monitoring</i> 36(4) 519–527. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000000033\">10.1097/FTD.0000000000000033</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24365987/\">https://pubmed.ncbi.nlm.nih.gov/24365987</a></p></li><li><p>Piqué, JM, et al., &amp; Hasselgren, G (2002). Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. <i>Clinical pharmacokinetics</i> 41(12) 999–1004. DOI:<a href=\"https://doi.org/10.2165/00003088-200241120-00004\">10.2165/00003088-200241120-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12222996/\">https://pubmed.ncbi.nlm.nih.gov/12222996</a></p></li><li><p>McCann, S, et al., &amp; Gonzalez, D (2023). Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease. <i>Clinical pharmacokinetics</i> 62(7) 997–1009. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01254-2\">10.1007/s40262-023-01254-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37179512/\">https://pubmed.ncbi.nlm.nih.gov/37179512</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A02BC01_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Omeprazole_1;
